Solid Biosciences Gets Wall Street Boost: Guggenheim Initiates Buy, Cites Advantage Over Sarepta in DMD

Guggenheim starts SLDB coverage with Buy rating and $26 price target. SGT-003 gene therapy shows safer profile vs Sarepta's Elevidys, eyes accelerated FDA approval.